Through NVIDIA Inception program, selected companies gain access to GPU technologies, software development tools, technical training, and venture capital connections—aimed at accelerating innovation in frontier industries.
FirstBioTherapeutics is applying AI technologies to improve the speed and accuracy of small-molecule drug discovery, aiming to increase the success rate in identifying viable drug candidates. As part of the Inception program, the company will leverage NVIDIA’s development kits and the BioNeMo generative AI platform to refine protein structure predictions and optimize molecular design.
In collaboration with NVIDIA’s development team, FirstBioTherapeutics will refine its proprietary AI models, incorporate expert technical feedback, and participate in global conferences to broaden its industry partnerships.
“Joining NVIDIA Inception significantly strengthens our AI capabilities for drug development, allowing us to improve both research efficiency and predictive performance,” said Jae-eun Kim, CEO of FirstBioTherapeutics.
In a separate achievement, FirstBioTherapeutics was designated as a “preliminary unicorn” by South Korea’s Ministry of SMEs and Startups in 2024. The company is also partnering with Naver Cloud and Dassault Systèmes to advance its AI-based drug development initiatives.
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr